Avicanna Announces Closing of Strategic Non-Brokered Private Placement

Strategic investment by pharmaceutical executive and life sciences investor Michael Porter TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the closing of a strategic non-brokered private […]